The brain's mechanism for controlling ageing has been discovered and manipulated to shorten and extend the lives of mice. Drugs to slow ageing could follow
Tick tock, tick tock
A mechanism that controls ageing, counting down to inevitable death, has been identified in the hypothalamus  a part of the brain that controls most of the basic functions of life.
By manipulating this mechanism, researchers have both shortened and lengthened the lifespan of mice. The discovery reveals several new drug targets that, if not quite an elixir of youth, may at least delay the onset of age-related disease.
While investigating ageing processes in the brain, Cai and his colleagues noticed that ageing mice produce increasing levels of nuclear factor kB (NF-kB)    a protein complex that plays a major role in regulating immune responses. NF-kB is barely active in the hypothalamus of 3 to 4-month-old mice but becomes very active in old mice, aged 22 to 24 months.
To see whether it was possible to affect ageing by manipulating levels of this protein complex, Cai's team tested three groups of middle-aged mice. One group was given gene therapy that inhibits NF-kB, the second had gene therapy to activate NF-kB, while the third was left to age naturally.
This last group lived, as expected, between 600 and 1000 days. Mice with activated NF-kB all died within 900 days, while the animals with NF-kB inhibition lived for up to 1100 days.
Crucially, the mice that lived the longest not only increased their lifespan but also remained mentally and physically fit for longer.
Six months after receiving gene therapy, all the mice were given a series of tests involving cognitive and physical ability.
In all of the tests, the mice that subsequently lived the longest outperformed the controls, while the short-lived mice performed the worst.
To see if they could control lifespan using this hormone, the team gave another group of mice   20 to 24 months old   daily subcutaneous injections of GnRH for five to eight weeks. These mice lived longer too, by a length of time similar to that of mice with inhibited NF-kB.
GnRH injections also resulted in new neurons in the brain. What's more, when injected directly into the hypothalamus, GnRH influenced other brain regions, reversing widespread age-related decline and further supporting the idea that the hypothalamus could be a master controller for many ageing processes.
GnRH injections even delayed ageing in the mice that had been given gene therapy to activate NF-kB and would otherwise have aged more quickly than usual. None of the mice in the study showed serious side effects.
So could regular doses of GnRH keep death at bay? Cai hopes to find out how different doses affect lifespan, but says the hormone is unlikely to prolong life indefinitely since GnRH is only one of many factors at play. "Ageing is the most complicated biological process," he says.
"There are dozens of pathways that people will look at thanks to this work," says Richard Miller at the University of Michigan in Ann Arbor. Miller has previously demonstrated that an immunosuppressant drug called rapamycin can also extend life in mice (see "A guide to defying age").
Since the hypothalamus   and GnRH in particular   regulate several major biological processes, it may be possible to influence ageing through related mechanisms, says Miller. He wants to look at possible dietary interventions, such as the indirect effect that spikes in glucose may have on the hypothalamus.
Stuart Maudsley at the National Institute on Aging in Baltimore, Maryland, agrees that the hypothalamus could be the route in for age-controlling drugs. "The body is all one big juicy system," he says. The ideal drug would hit that system at its centre. "Activate that keystone and everything falls into place," he says.
Though this is the first time that an explicit role has been found for GnRH in the ageing process, previous studies in humans have hinted at a link between longevity and fertility  in which the hormone is known to play a significant role.
"There are maybe 10 steps to controlling ageing," says Miller. "We've taken the first two or three." The first is simply accepting the idea that ageing can be slowed down, he says. "Many think it can't. They are wrong."
Maudsley reckons that we could see drugs that slow ageing in the next 20 years. Initially, though, research is likely to focus on delaying the onset of age-related diseases. "That could solve some real problems," says Cai.
But since the hypothalamus has an effect on every cell in the body, Maudsley warns that interfering with it could lead to unwanted sequences of events. "You're playing with fire," he says.
Journal reference: Nature, 10.1038/nature12143
